Jung In Duk, Lee Jun Sik, Kim Yong Joo, Jeong Young-Il, Lee Chang-Min, Baumruker Thomas, Billlich Andreas, Banno Yoshiko, Lee Min Goo, Ahn Soon-Choel, Park Won Sun, Han Jin, Park Yeong-Min
Department of Microbiology and Immunology, National Research Laboratory of Dendritic Cell Differentiation and Regulation, Medical Research Institute, College of Medicine, Pusan National University, Ami-dong 1-10, Seo-gu, Busan 602-739, Korea.
Int Immunol. 2007 Apr;19(4):411-26. doi: 10.1093/intimm/dxm006. Epub 2007 Feb 16.
Sphingosine kinase (Sphk) has been shown to be activated by growth factor and survival factors, and one of its products, sphingosine-1-phosphate, plays an important role in the regulation of various cellular responses. However, the effect of Sphk on the maturation and immunostimulatory function of dendritic cells (DCs) still remains largely unknown. In this study, we examined whether sphingosine kinase inhibitor (SKI) can influence co-stimulatory molecules (CD40, CD80, CD86 and MHC class II) and cytokine production (IL-12 and IL-10) in murine bone marrow-derived DCs. SKI significantly inhibited co-stimulatory molecules in DCs. SKI suppressed IL-12 production by DCs and IFN-gamma production by T cells. In addition, SKI-inhibited LPS induced the translocation of nuclear factor-kappaB, whereas it did not affect the degradation of IL-1 receptor-associated kinase-1 by LPS. These novel findings provide new insight into the immunopharmacological role of SKI in terms of its effects on DCs. These findings open a possibility for further understanding of the immunopharmacological functions of SKI, as well as therapeutic adjuvants for the treatment of DC-related acute and chronic diseases.
鞘氨醇激酶(Sphk)已被证明可被生长因子和存活因子激活,其产物之一鞘氨醇-1-磷酸在调节各种细胞反应中起重要作用。然而,Sphk对树突状细胞(DCs)成熟和免疫刺激功能的影响仍 largely unknown。在本研究中,我们检测了鞘氨醇激酶抑制剂(SKI)是否能影响小鼠骨髓来源DCs中共刺激分子(CD40、CD80、CD86和MHC II类分子)和细胞因子产生(IL-12和IL-10)。SKI显著抑制DCs中的共刺激分子。SKI抑制DCs产生IL-12以及T细胞产生IFN-γ。此外,SKI抑制LPS诱导的核因子-κB易位,而不影响LPS诱导的IL-1受体相关激酶-1降解。这些新发现为SKI对DCs作用方面的免疫药理学作用提供了新见解。这些发现为进一步理解SKI的免疫药理学功能以及治疗DC相关急慢性疾病的治疗佐剂开辟了可能性。 (注:“largely unknown”直译为“很大程度上未知”,这里保留英文表述更符合语境;最后的“治疗佐剂”根据语境意译,原文是说可能成为治疗相关疾病的辅助手段)